Evidence map›Paper›PMID 34943685›Full record

ReviewAntibiotics (Basel, Switzerland)2021

Nanotechnology as a Novel Approach in Combating Microbes Providing an Alternative to Antibiotics.

Bismillah Mubeen, Aunza Nayab Ansar, Rabia Rasool, Inam Ullah, Syed Sarim Imam, Sultan Alshehri, Mohammed M Ghoneim, Sami I Alzarea, Muhammad Shahid Nadeem, Imran Kazmi

Open access · goldAbstract readReview
In one paragraph

Review in Antibiotics (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 85 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
85citing papers in PubMed, 1 pooled it
7.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

85 citing papers in PubMed, 1 synthesis or guideline pooled it, 221 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article

25 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Bismillah MubeenInstitute of Molecular Biology and Biotechnology, The University of Lahore, Lahore 54000, Pakistan.ORCID 0000-0002-4095-6467
Aunza Nayab AnsarInstitute of Molecular Biology and Biotechnology, The University of Lahore, Lahore 54000, Pakistan.ORCID 0000-0001-6050-3767
Rabia RasoolInstitute of Molecular Biology and Biotechnology, The University of Lahore, Lahore 54000, Pakistan.
Inam UllahInstitute of Molecular Biology and Biotechnology, The University of Lahore, Lahore 54000, Pakistan.ORCID 0000-0002-1614-6456
Syed Sarim ImamDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-8913-0826
Sultan AlshehriDepartment of Pharmaceutics, College of Pharmacy, King Saud University, Riyadh 11451, Saudi Arabia.ORCID 0000-0002-0922-9819
Mohammed M GhoneimDepartment of Pharmacy Practice, College of Pharmacy, AlMaarefa University, Ad Diriyah 13713, Saudi Arabia.ORCID 0000-0002-9179-4373
Sami I AlzareaDepartment of Pharmacology, College of Pharmacy, Jouf University, Sakaka 72341, Saudi Arabia.ORCID 0000-0003-4007-4023
Muhammad Shahid NadeemDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0003-4112-0925
Imran KazmiDepartment of Biochemistry, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia.ORCID 0000-0003-1881-5219
University of Lahore · PKKing Abdulaziz University · SAKing Saud University · SAAlfaisal University · SAJouf University · SA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The emergence of infectious diseases promises to be one of the leading mortality factors in the healthcare sector. Although several drugs are available on the market, newly found microorganisms carrying multidrug resistance (MDR) against which existing drugs cannot function effectively, giving rise to escalated antibiotic dosage therapies and the need to develop novel drugs, which require time, money, and manpower. Thus, the exploitation of antimicrobials has led to the production of MDR bacteria, and their prevalence and growth are a major concern. Novel approaches to prevent antimicrobial drug resistance are in practice. Nanotechnology-based innovation provides physicians and patients the opportunity to overcome the crisis of drug resistance. Nanoparticles have promising potential in the healthcare sector. Recently, nanoparticles have been designed to address pathogenic microorganisms. A multitude of processes that can vary with various traits, including size, morphology, electrical charge, and surface coatings, allow researchers to develop novel composite antimicrobial substances for use in different applications performing antimicrobial activities. The antimicrobial activity of inorganic and carbon-based nanoparticles can be applied to various research, medical, and industrial uses in the future and offer a solution to the crisis of antimicrobial resistance to traditional approaches. Metal-based nanoparticles have also been extensively studied for many biomedical applications. In addition to reduced size and selectivity for bacteria, metal-based nanoparticles have proven effective against pathogens listed as a priority, according to the World Health Organization (WHO). Moreover, antimicrobial studies of nanoparticles were carried out not only in vitro but in vivo as well in order to investigate their efficacy. In addition, nanomaterials provide numerous opportunities for infection prevention, diagnosis, treatment, and biofilm control. This study emphasizes the antimicrobial effects of nanoparticles and contrasts nanoparticles' with antibiotics' role in the fight against pathogenic microorganisms. Future prospects revolve around developing new strategies and products to prevent, control, and treat microbial infections in humans and other animals, including viral infections seen in the current pandemic scenarios.

Indexed as

antimicrobial resistance growthbiogenic nanoparticlesconventional antibioticsemergence of infectious diseasehealthcare sectormultidrug resistance (MDR)nanotechnology-based innovationpathogenic microorganisms

Identifiers

PMID34943685
PMCPMC8698349
OpenAlexW3215389368

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.